Comparative Pharmacology
Head-to-head clinical analysis: QOLIANA versus TYLENOL W CODEINE NO 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QOLIANA versus TYLENOL W CODEINE NO 2.
QOLIANA vs TYLENOL W/ CODEINE NO. 2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Acetaminophen: Inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis, with weak peripheral COX inhibition. Codeine: Prodrug converted to morphine via CYP2D6; morphine acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
1 to 2 tablets (300 mg acetaminophen/15 mg codeine phosphate per tablet) orally every 4 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Acetaminophen: 2-3 hours. Codeine: 2.5-3.5 hours. In hepatic impairment, half-life of codeine may be prolonged.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Renal: 70-80% as glucuronide and sulfate conjugates of acetaminophen, 5-10% as unchanged acetaminophen, and 5-10% as unchanged codeine. Biliary/fecal: minor, <5%.
Category C
Category D/X
Opioid Agonist
Opioid Agonist